Aurobindo Pharma will commence supplies to Europe from its China-based facility starting April 2025. The Hyderabad-based pharmaceutical firm initiated operations at the China plant in late November 2024 and is now ramping up production. The company has secured European regulatory approvals, allowing it to begin product supply, he added. \”We are in the process of getting it (in China) and after that, there may be an inspection for the US (market) also,\” Subramanian noted, suggesting potential expansion into the American market. On the company’s biologics business, a director said the segment is expected to reach a major inflection point between 2028 and 2030. He said the company has three products that are approved, two with a positive opinion in Europe, one in the UK, and we expect one more this year. With Denosumab, Omalizumab and another product coming next year, we anticipate at least seven biosimilars to be fully commercialized by 2027-28,\” he said.
